Eliza B Geer1, Roberto Salvatori2, Atanaska Elenkova3, Maria Fleseriu4, Rosario Pivonello5, Przemyslaw Witek6, Richard A Feelders7, Marie Bex8, Stina W Borresen9, Soraya Puglisi10, Beverly M K Biller11, Fredric Cohen12, Francesca Pecori Giraldi13,14. 1. Memorial Sloan Kettering Cancer Center, New York, NY, USA. geere@mskcc.org. 2. Johns Hopkins University, Baltimore, MD, USA. 3. Medical University Sofia, Sofia, Bulgaria. 4. Oregon Health and Science University, Portland, OR, USA. 5. Università Federico II di Napoli, Naples, Italy. 6. Department of Internal Diseases, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, Poland. 7. Erasmus Medical Center, Rotterdam, The Netherlands. 8. University Hospitals Leuven, Leuven, Belgium. 9. Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 10. Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy. 11. Massachusetts General Hospital, Boston, MA, USA. 12. Strongbridge Biopharma, Trevose, PA, USA. 13. Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy. 14. Neuroendocrinology Research Laboratory, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Abstract
PURPOSE: The efficacy of levoketoconazole in treating hypercortisolism was demonstrated in an open-label phase 3 study (SONICS) of adults with endogenous Cushing's syndrome (CS) and baseline mean urinary free cortisol (mUFC) ≥ 1.5× ULN. Clinical signs and symptoms and patient-reported outcomes from the SONICS trial were evaluated in the current manuscript. METHODS: Patients titrated to an individualized therapeutic dose entered a 6-month maintenance phase. Secondary endpoints included investigator-graded clinical signs and symptoms of CS during the maintenance phase, and patient-reported quality of life (CushingQoL questionnaire) and depression symptoms (Beck Depression Inventory II [BDI-II]). RESULTS: Of 94 enrolled patients, 77 entered the maintenance phase following individualized dose titration. Significant mean improvements from baseline were noted at end of maintenance (Month 6) for acne, hirsutism (females only), and peripheral edema. These improvements were observed as early as Day 1 of maintenance for hirsutism (mean baseline score, 7.8; ∆ - 1.9; P < 0.0001), end of Month 1 for acne (mean baseline score, 2.8; ∆ - 1.2; P = 0.0481), and Month 4 for peripheral edema (mean baseline score, 1.0; ∆ - 0.5; P = 0.0052). Significant mean improvements from baseline were observed by Month 3 of maintenance for CushingQoL (mean baseline score, 44.3; ∆ + 6.9; P = 0.0018) and at Month 6 for BDI-II (mean baseline score, 17.1; ∆ - 4.3; P = 0.0043) scores. No significant mean improvement was identified in a composite score of 7 other clinical signs and symptoms. CONCLUSIONS: Treatment with levoketoconazole was associated with sustained, meaningful improvements in QoL, depression, and certain clinical signs and symptoms characteristic of CS. ClinialTrials.gov identifier: NCT01838551.
PURPOSE: The efficacy of levoketoconazole in treating hypercortisolism was demonstrated in an open-label phase 3 study (SONICS) of adults with endogenous Cushing's syndrome (CS) and baseline mean urinary free cortisol (mUFC) ≥ 1.5× ULN. Clinical signs and symptoms and patient-reported outcomes from the SONICS trial were evaluated in the current manuscript. METHODS:Patients titrated to an individualized therapeutic dose entered a 6-month maintenance phase. Secondary endpoints included investigator-graded clinical signs and symptoms of CS during the maintenance phase, and patient-reported quality of life (CushingQoL questionnaire) and depression symptoms (Beck Depression Inventory II [BDI-II]). RESULTS: Of 94 enrolled patients, 77 entered the maintenance phase following individualized dose titration. Significant mean improvements from baseline were noted at end of maintenance (Month 6) for acne, hirsutism (females only), and peripheral edema. These improvements were observed as early as Day 1 of maintenance for hirsutism (mean baseline score, 7.8; ∆ - 1.9; P < 0.0001), end of Month 1 for acne (mean baseline score, 2.8; ∆ - 1.2; P = 0.0481), and Month 4 for peripheral edema (mean baseline score, 1.0; ∆ - 0.5; P = 0.0052). Significant mean improvements from baseline were observed by Month 3 of maintenance for CushingQoL (mean baseline score, 44.3; ∆ + 6.9; P = 0.0018) and at Month 6 for BDI-II (mean baseline score, 17.1; ∆ - 4.3; P = 0.0043) scores. No significant mean improvement was identified in a composite score of 7 other clinical signs and symptoms. CONCLUSIONS: Treatment with levoketoconazole was associated with sustained, meaningful improvements in QoL, depression, and certain clinical signs and symptoms characteristic of CS. ClinialTrials.gov identifier: NCT01838551.
Authors: Maria Fleseriu; Beverly M K Biller; James W Findling; Mark E Molitch; David E Schteingart; Coleman Gross Journal: J Clin Endocrinol Metab Date: 2012-03-30 Impact factor: 5.958
Authors: Leonie H A Broersen; Cornelie D Andela; Olaf M Dekkers; Alberto M Pereira; Nienke R Biermasz Journal: J Clin Endocrinol Metab Date: 2019-11-01 Impact factor: 5.958
Authors: B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro Journal: J Clin Endocrinol Metab Date: 2008-04-15 Impact factor: 5.958
Authors: Kimberly G Brodovicz; Kristin McNaughton; Naoto Uemura; Gary Meininger; Cynthia J Girman; Steven H Yale Journal: Clin Med Res Date: 2009-02-26
Authors: J M Hinojosa-Amaya; E V Varlamov; C G Yedinak; J S Cetas; S McCartney; S Banskota; M Fleseriu Journal: J Endocrinol Invest Date: 2021-04-24 Impact factor: 4.256
Authors: Thomas Cuny; Thomas Graillon; Célines Defilles; Rakesh Datta; Shengwen Zhang; Dominique Figarella-Branger; Henry Dufour; Grégory Mougel; Thierry Brue; Tanya Landsman; Heather A Halem; Michael D Culler; Anne Barlier; Alexandru Saveanu Journal: Pituitary Date: 2021-01-12 Impact factor: 4.107